Topic:

R&D

Latest Headlines

Latest Headlines

Baxalta bets on 'external innovation' to meet its $8.5B goal and ward off Shire

Baxalta is hoping to launch 20 new drugs by 2020, and the nearly 2-month-old company is taking a decentralized approach to R&D on the way there, relying on partners to handle early-stage work before finishing projects itself.

Silicon Valley startup raises $55M to offer second opinions prior to surgery

San Francisco startup Grand Rounds is offering second opinions to cut down on unnecessary or inappropriate surgeries. It just announced a $55 million VC haul, to take its total to $106 million.

Lundbeck's big reorg will help fund R&D on new antipsychotic med

As Lundbeck cuts staff and reshuffles R&D, one of its drug candidates has come out a winner.

Devicemakers clamor for Google Glass with product updates on the horizon

Google has faced some stumbling blocks with Google Glass since launching the product in 2013, deciding earlier this year to stop selling the device to consumers in light of waning sales. But the company is set to meet increased demand for the product among devicemakers as a new version of Glass hits the market.    

Team outlines potential target for aggressive breast cancer vaccine

Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed. 

Pfenex enters anthrax vaccines realm with $143.5M BARDA contract

While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.

Lundbeck to advance schizophrenia drug solo after taking an ax to early-stage pipeline

Lundbeck has initiated a rejig of its pipeline, taking an ax to undisclosed early-stage assets in order to funnel cash into what it sees as its most promising candidates. The schizophrenia drug Lu AF35700 is among the beneficiaries of the reshuffle, with Lundbeck using its reorganized balance sheet to advance the therapy through development unpartnered.

A biotech startup grows out of GlaxoSmithKline's discarded NC R&D

GlaxoSmithKline is laying off nearly 1,000 employees in North Carolina in an effort to trim its R&D costs, cutting deep into the biotech ecosystem in Research Triangle Park. But a handful of ex-GSK researchers have swiftly moved on, starting up a biotech to develop peptide therapies of their own.

Reborn Akari grabs $75M in financing for another Soliris rival

Six months after Celsus Therapeutics' stock price collapsed on the mid-stage failure of its lead therapy, Geneva-based Volution Immuno Pharmaceuticals has stepped in with a reverse merger deal, lining up $75 million in fresh financing from some A-list investors and flipping the company into the public market with a new name and ticker symbol on Nasdaq.

Intarcia's diabetes-treating implant tops Januvia in a head-to-head test

Intarcia Therapeutics' matchstick-sized device for diabetes beat out Merck's blockbuster drug Januvia in a Phase III trial, burnishing its case for FDA approval next year.